speaker-photo

Pete Brockmeier

Global Associate Director, Digital Health at Novo Nordisk
Pete has spent his career at the intersection of digital technology and life sciences, continuously innovating across the value chain with diverse roles in research, development and now partnerships and commercialization. He holds BS and MS degrees in engineering (Mechanical and Biomedical) and began his career in medical device development. Pete joined Novo Nordisk in 2013 and the Digital Health organization in 2017, where he has led product teams in the development of DTx products. He is currently Associate Director of Digital Health Partnerships, responsible for establishing and commercializing a portfolio of DTx and SaMD partnerships in the Diabetes Therapy Area.

 

Pete Brockmeier

Global Associate Director, Digital Health

Novo Nordisk

Linkedin Logo

15:40-16:20 PM

Thursday 07th Nov

Drug + Digital as the Future Standard of Care? Considerations for Achieving Success with DTx Drug Companion Solutions

Across many industries, modern products include a digital component, enabling personalization, enhanced experiences, and generating valuable data for customers and companies.

In medicine, “drug + digital" offerings can similarly improve patient experiences and outcomes, leveraging clinically validated DTx companion apps to simplify and optimize medication use. However, the adoption of these solutions has been challenged by regulatory and distribution complexities and unclear or lacking incentives for key stakeholders in the value chain.

This talk will explore practical strategies to overcome these hurdles and effectively deliver DTx drug companion apps to patients, unlocking their potential benefits.

 

Pete Brockmeier
Global Associate Director, Digital Health
Novo Nordisk

Linkedin Logo